Brokerages predict that FibroGen Inc (NASDAQ:FGEN) will report $33.09 million in sales for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for FibroGen’s earnings, with estimates ranging from $26.64 million to $46.80 million. FibroGen posted sales of $191.57 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 82.7%. The business is expected to announce its next earnings results on Thursday, August 13th.
On average, analysts expect that FibroGen will report full year sales of $225.93 million for the current year, with estimates ranging from $115.48 million to $282.00 million. For the next fiscal year, analysts anticipate that the business will report sales of $412.57 million, with estimates ranging from $322.94 million to $495.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow FibroGen.
FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.50). The business had revenue of $24.40 million during the quarter, compared to the consensus estimate of $72.58 million. FibroGen had a negative net margin of 42.75% and a negative return on equity of 19.32%. FibroGen’s revenue was up 2.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.53) earnings per share.
Shares of FibroGen stock traded up $0.24 on Monday, hitting $36.82. The company had a trading volume of 277,598 shares, compared to its average volume of 696,577. The stock has a 50-day moving average of $36.79 and a 200-day moving average of $39.96. The company has a debt-to-equity ratio of 0.07, a current ratio of 11.14 and a quick ratio of 11.01. FibroGen has a twelve month low of $22.65 and a twelve month high of $48.95. The firm has a market capitalization of $3.26 billion, a P/E ratio of -27.89 and a beta of 1.53.
In other news, SVP Christine Chung sold 7,345 shares of the business’s stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $25.91, for a total transaction of $190,308.95. Following the transaction, the senior vice president now directly owns 122,518 shares in the company, valued at approximately $3,174,441.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Pat Cotroneo sold 9,239 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $26.36, for a total transaction of $243,540.04. Following the completion of the sale, the chief financial officer now directly owns 245,705 shares in the company, valued at $6,476,783.80. The disclosure for this sale can be found here. Insiders have sold a total of 34,584 shares of company stock worth $850,909 in the last ninety days. Insiders own 8.96% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in FGEN. Goldman Sachs Group Inc. boosted its stake in shares of FibroGen by 20.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,048,453 shares of the biopharmaceutical company’s stock worth $44,968,000 after acquiring an additional 174,518 shares during the period. Assenagon Asset Management S.A. acquired a new stake in FibroGen during the 4th quarter valued at $3,091,000. FMR LLC boosted its position in FibroGen by 8.1% during the fourth quarter. FMR LLC now owns 9,434,188 shares of the biopharmaceutical company’s stock worth $404,632,000 after purchasing an additional 706,703 shares during the period. Jacobs Levy Equity Management Inc. increased its holdings in shares of FibroGen by 28.1% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 194,826 shares of the biopharmaceutical company’s stock valued at $8,356,000 after purchasing an additional 42,760 shares during the last quarter. Finally, Knights of Columbus Asset Advisors LLC bought a new position in shares of FibroGen in the fourth quarter valued at about $1,379,000. 68.10% of the stock is owned by institutional investors.
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Featured Article: Intrinsic Value and Stock Selection
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.